NCT04867603View on ClinicalTrials.gov

Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions

CompletedOBSERVATIONAL
Enrollment

16

Participants

Timeline

Start Date

June 29, 2021

Primary Completion Date

October 3, 2022

Study Completion Date

October 3, 2022

Conditions
Prostate Cancer
Interventions
DRUG

[Ga-68]PSMA

The injectable activity will be a maximum of 210 MBq (6.0 mCi) \[Ga-68\]PSMA at the time of injection and is administered to subjects by intravenous injection.

DEVICE

PET/CT imaging

PET/CT imaging procedure

Trial Locations (1)

44106-5065

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Norbert Avril, M.D.

OTHER